Cambium Bio (CMB.AX) Stock Price

Cambium Bio Price

ASX·CLOSED
0.45
​
Market closed

Revenue at Cambium Bio has contracted by 19.7% per year over the past 26 years to 641,638.00 AUD. Earnings per share have declined at 20.4% per year over the last 21 years. Cambium Bio's net margin stands at -638.4%, down from -53.7% several years earlier.

Cambium Bio stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cambium Bio business model & stock analysis

Cambium Bio Ltd, trading under the ticker CMB.AX with ISIN AU0000327769, is an Australian company operating in the Health Care sector within the Biotechnology industry. The company went public via an IPO on September 19, 2013. Its website is https://regeneus.com.au/. Cambium Bio Ltd is engaged in regenerative medicine, utilizing stem cell technologies to develop cell-based therapies. The company has two primary platform technologies: Progenza and Sygenus. Progenza, which has been licensed to Kyocera for the treatment of knee osteoarthritis in Japan, is a cellular therapy targeting pain and inflammation. It uses Secretome to enhance both resident tissue and Mesenchymal Signalling Cells (MSCs). Sygenus is a cell-free topical serum and gel treatment for pain and inflammation, currently in pre-clinical development. The company focuses on addressing unmet medical needs in areas such as osteoarthritis, neuropathic pain, and various skin conditions. Regeneus, the company's website domain, suggests a connection to regenerative medicine, though the company's current name is Cambium Bio Ltd. The company's headquarters location is unknown, and it is listed on the Australian stock exchange. The company's product pipeline includes therapies targeting specific medical conditions, with Progenza already licensed for a specific application in Japan. The company's focus on regenerative medicine positions it within the broader biotechnology sector, aiming to develop novel treatments for chronic conditions. No additional details regarding acquisitions, specific founding year, or other personnel are provided in the available information.

Frequently asked questions about Cambium Bio

Converted at the current exchange rate, the Cambium Bio share trades at 0.28 EUR (0.45 AUD).

The Cambium Bio share (CMB.AX) is listed on 1 stock exchanges, including: ASX (RGS.AX).

The revenue of Cambium Bio is 641,638.00 AUD. This figure is based on current financial data and reflects the company's business performance.

The profit of Cambium Bio is -4.10 M AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Cambium Bio is currently -2.79. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cambium Bio stock.

The price-to-sales ratio (P/S) of Cambium Bio is currently 17.82. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Cambium Bio stock.

The Eulerpool Quality Score for Cambium Bio is 2/10.

The ISIN of Cambium Bio is AU0000327769. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Cambium Bio is CMB.AX. The ticker symbol is used to trade Cambium Bio shares on the stock exchange.

Fair ValueTerminal
0.37 AUD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Australia
Currency
AUD
Initial public offering
Sep 19, 2013
ISIN
AU0000327769
Cusip
Q80525100
Market capitalization
10.34 M AUDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2027
-497.76
P/Ee 2028
-165.92
P/Se
14.38
EV/EBIT
—
P/B Ratio
4.34
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-161.01 %
Last updated Oct 16, 2026, 6:03 PM

Cambium Bio Peer Group

Cambium Bio Ticker

ASX · RGS.AX